Citations

Clear

367 citation(s) found for "Benson, Al".

Abstract WMP108: Pericarotid Fat Associated with Major Adverse Cardiovascular Events after Carotid Endarterectomy
Kalina, Samuel, Saba, Luca , Nardi, Valentina , Lerman, Amir, Nardi, Valentina , Nardi, Valentina , Kalina, Samuel, Nogami, Kai , Mahmoudi, Elham , Hamidabad, Negin Mahmoudi , Benson, John C. , Saba, Luca , Lanzino, Giuseppe , Lerman, Amir

Mayo Clinic

Stroke | January 30, 2025 | Volume: 56 | Issue: Suppl_1 | Pages: No page available

10.1161/str.56.suppl_1.wmp108 Get It

Background: Previous studies have linked pericoronary artery adipose tissue attenuation to major adverse cardiac event (MACE). However, the association between pericarotid artery fat and prognosis remains underexplored. This study aimed to investigate the association between preoperative pericarotid fat characteristics and the subsequent prognosis in patients undergoing carotid endarterectomy (CEA). Methods: This study included patients with preoperative computed tomography angiography (CTA) followed by CEA. Preoperative neck CTA images were obtained and analyzed with novel methods using 3D Slicer software. We segmented the common and internal carotid arteries. The segment was horizontally trimmed, isolating the region around the bifurcation, extending 15 mm above and 10 mm below. Pericarotid fat was defined as adipose tissue within a 5 mm radial distance from the outer vessel wall, with Hounsfield units (HU) between -190 and -30 (Figure 1, carotid segmentation [green] and pericarotid fat [yellow]) . For each patient, we calculated the HU average and the volume (mm3) of the pericarotid fat. MACE was defined as a composite of all-cause mortality, myocardial infarction, and cerebrovascular events. The relationship between both pericarotid fat characteristics and MACE was investigated. Results: Of the 43 patients initially included, one was excluded due to an inability to perform segmentation caused by chronic total occlusion, leaving 42 patients (age 73 [67-78] years, 33 [76.7%] male). The comparison of mean pericarotid fat HU between the ipsilateral and contralateral sides showed no significant difference (-60.3±11.0 HU vs. -60.9 ±11.3 HU, p=0.437). However, the median ipsilateral fat volume was significantly higher than the contralateral volume (528 [248, 1100] mm3 vs. 328 [184, 697] mm3, p=0.020). When comparing patients with and without MACE, those with MACE had a significantly lower ipsilateral fat density (-59.4±10.2 HU vs. -66.8 ±11.1 HU, p=0.022) and a higher fat volume (468 [233, 746] mm3 vs. 845 [458, 1451] mm3, p=0.044). Kaplan-Meier analysis revealed that higher volume and lower fat density than the median were significant predictors of MACE (log-rank p=0.015 and p=0.042, respectively) (Figure 2). Conclusions: Assessment of pericarotid fat using a novel CTA analytic method in patients undergoing CEA identified ipsilateral lower fat density and higher fat volume as predictors of adverse outcomes.
Abstract TP342: Associations Between Pericarotid Fat Density and Carotid Plaque Inflammatory Cytokine Levels
Kalina, Samuel, Saba, Luca , Nardi, Valentina , Nardi, Valentina , Nardi, Valentina , Kalina, Samuel, Nogami, Kai , Hamidabad, Negin Mahmoudi , Mahmoudi, Elham , Benson, John C. , Saba, Luca , Lanzino, Giuseppe , Lerman, Amir

Mayo Clinic

Stroke | January 30, 2025 | Volume: 56 | Issue: Suppl_1 | Pages: No page available

10.1161/str.56.suppl_1.tp342 Get It

Background: Previous research has suggested pericarotid fat density to be significantly linked to atherosclerotic plaque components and cerebrovascular events. Inflammatory markers within the plaques are critical in the pathogenesis and progression of carotid artery disease. However, the association between pericarotid fat and inflammatory processes within atherosclerotic plaques remains underexplored. This study hypothesizes that pericarotid fat density is directly associated with the levels of inflammatory markers within atherosclerotic plaques. Methods: Carotid plaques were prospectively collected from patients with carotid artery disease undergoing carotid endarterectomy (CEA). The levels of inflammatory plaque cytokines (MCP-1, IL-8, IFN-γ, IL-10, IL-1β, IL-6, PDGF-AA, PDGF-AB/BB, TNF-α, VEGF) were measured in tissue homogenates using a customized 10-plex Luminex assay. Baseline demographics and clinical data of our population were extracted from electronic health records. We analyzed preoperative neck computed tomography angiography (CTA) images placing regions-of-interest (ROI) in the pericarotid fat on the slice showing maximal stenosis. For each patient, we calculated the average of Hounsfield Units (HU) within the ROI. Spearman correlation test was used to assess the correlation between variables. Results: Among the 43 patients included, the median age was 73 (67, 78) years, and 33 (76.7%) patients were male. Plaque levels of PDGF-AA and VEGF showed significant positive correlations with HU (r=0.330, p=0.030; r=0.380, p=0.011, respectively), as illustrated in Figure 1 . Although plaque levels of IFN-γ demonstrated a significant negative correlation with HU (r=-0.390, p=0.010), the most cases exhibited values close to zero. Conclusions: The assessment of pericarotid fat density on CTA may allow for the estimation of plaque inflammation, suggesting that more fat density is associated with increased inflammatory activity within atherosclerotic plaques.
Abstract WP205: Association Between Bovine Aortic Arch Anatomy and Carotid Artery Stenosis
Kalina, Samuel, Saba, Luca , Nardi, Valentina , Lerman, Amir, Nardi, Valentina , Nardi, Valentina , Kalina, Samuel, Hamidabad, Negin Mahmoudi , Benson, John C. , Nogami, Kai , Mahmoudi, Elham , Saba, Luca , Lanzino, Giuseppe , Lerman, Amir

Mayo Clinic

Stroke | January 30, 2025 | Volume: 56 | Issue: Suppl_1 | Pages: No page available

10.1161/str.56.suppl_1.wp205 Get It

Background: The bovine aortic arch is a vascular variant in which the left common carotid artery originates from the brachiocephalic trunk rather than directly from the aortic arch. The bovine anatomical variation may alter the blood flow dynamics, potentially contributing to the formation and progression of carotid plaques. In this study, we evaluated the association of the bovine aortic arch and the severity of carotid stenosis. Methods: In this retrospective study, we included patients with carotid artery disease undergoing carotid endarterectomy (CEA) and pre-surgical computed tomography angiography (CTA). CTAs were reviewed to assess the carotid stenosis and the anatomy of the aortic arch. The left carotid artery was classified as normal if it originated from the aortic arch and as bovine if it originated from the brachiocephalic trunk (Figure 1) . Unlimited propensity score matching was performed to balance baseline characteristics between patients with bovine and normal anatomies. The Mann-Whitney U test was applied to compare carotid stenosis between bovine and normal arteries. Results: A total of 203 patients (bovine:23, normal:180) were initially enrolled. Using propensity score matching, 20 patients with bovine anatomy were matched to 45 patients with normal anatomy (Figure 2) . Among the 65 patients included, 47 (74.6%) were male, with a median age of 70 [IQR:65.0-76.0] years. Left-sided carotid artery disease was more prevalent in the bovine compared to normal group (N=12, 66.7% vs. N=16, 36.4%; p=0.030). Additionally, the severity of carotid stenosis in CEA-treated side was higher in patients with bovine arch compared to normal controls (82.5% [76.2-88.7] vs. 70.0% [50.0-95.0]; p=0.030) (Figure 3) . Conclusions: The association of a bovine aortic arch with more severe carotid stenosis suggests that this anatomical variant may be a marker for increased cerebrovascular risk.
Carotid artery atherosclerosis: mechanisms of instability and clinical implications
Saba, Luca , Cau, Riccardo , Vergallo, Rocco , Kooi, M. Eline , Congiu, Terenzio , Wasserman, Bruce A. , Nardi, Valentina , Kawakami, Rika , Ntaios, George , Kawakami, Rika , Lanzino, Giuseppe , Virmani, Renu , Libby, Peter , Cau, Riccardo , Nardi, Valentina , Kooi, Marianne Eline , Saba, Luca , Staub, Daniel , Faa, Gavino , Benson, John C. , Lanzino, Giuseppe , Virmani, Renu , Libby, Peter

Mayo Clinic

European Heart Journal | December 22, 2024 | Volume: 46 | Issue: 10 | Pages: 904-921

10.1093/eurheartj/ehae933 | PMID 39791527 Get It

Abstract Cardiovascular disease remains a prominent cause of disability and premature death worldwide. Within this spectrum, carotid artery atherosclerosis is a complex and multifaceted condition, and a prominent precursor of acute ischaemic stroke and other cardiovascular events. The intricate interplay among inflammation, oxidative stress, endothelial dysfunction, lipid metabolism, and immune responses participates in the development of lesions, leading to luminal stenosis and potential plaque instability. Even non-stenotic plaques can precipitate a sudden cerebrovascular event, regardless of the degree of luminal encroachment. In this context, carotid imaging modalities have proved their efficacy in providing in vivo characterization of plaque features, contributing substantially to patient risk stratification and clinical management. This review emphasizes the importance of identifying high-risk individuals by use of current imaging modalities, biomarkers, and risk stratification tools. Such approaches inform early intervention and the implementation of personalized therapeutic strategies, ultimately enhancing patient outcomes in the realm of cardiovascular disease management.
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline
Morris, Van K. , Kennedy, Erin B. , Amin, Manik , Aranha, Olivia , Benson, Al B. , Dorth, Jennifer A. , Horowitz, David P. , Kennecke, Hagen F. , Kim, Stéfano , Kreppel, Lillian, Rajdev, Lakshmi , Mettu, Niharika B , Riechelmann, Rachel , Sio, Terence T , Eng, Cathy , Riechelmann, Rachel P. , Sio, Terence T. , Eng, Cathy

Mayo Clinic

Journal of Clinical Oncology | December 16, 2024 | Volume: 43 | Issue: 5 | Pages: 605-615

10.1200/jco-24-02120 | PMID 39680825 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgement. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard-of-care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only). PURPOSE To provide evidence-based guidance for clinicians who treat patients with stage I-III anal cancer. METHODS A systematic review of the literature conducted by the Minnesota Evidence-based Practice Center provided the evidence base for this guideline. An ASCO Expert Panel reviewed this evidence and came to consensus on a set of evidence-based recommendations. RESULTS The systematic review contained three randomized controlled trials and three nonrandomized studies of interventions that were relevant to the guideline topic and informed the recommendations. RECOMMENDATIONS Mitomycin-C (MMC) with a fluoropyrimidine (fluorouracil [FU] or capecitabine) is recommended as the radiosensitizing component of chemoradiation (CRT) for anal cancer; the Expert Panel recognizes that capecitabine is often used as an orally administered alternative to FU and is currently being used in ongoing clinical trials. Cisplatin with FU is an additional chemotherapy combination that may be recommended as radiosensitizing chemotherapy. Because of the myelosuppression associated with MMC, the preferable regimen for patients with immunosuppression is cisplatin and FU. Cisplatin is not recommended for patients with renal dysfunction, significant neuropathy, or hearing loss, and there is no evidence to recommend substituting carboplatin for cisplatin. Dose and schedule options for recommended chemotherapy agents are included within the full text of the guideline. Routine induction chemotherapy before CRT and additional chemotherapy after CRT are not recommended for patients with localized anal cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Radiology-pathology correlation: Rosai–Dorfman disease
Benson, John C. , Pais, Alex B, Mark, Ian T. , Chen, John J. , Meyer, Frederic B., Giannini, Caterina, Tobin, William O, Benson, John , Mark, Ian , Chen, John J , Pais, Alex B, Tobin, W. Oliver , Hunt, Christopher H.

Mayo Clinic

The Neuroradiology Journal | November 20, 2024 | Volume: 38 | Issue: 3 | Pages: 299-303

10.1177/19714009241303077 | PMID 39567877 Get It

Rosai–Dorfman Disease (RDD), also known as sinus histiocytosis with massive lymphadenopathy, is a rare non-Langerhans cell histiocytic neoplasm. Although the disease classically presents as massive painless lymphadenopathy in young adults, RDD can also involve the central nervous system in some patients. CNS lesions, can cause headaches, neurologic deficits, and even neurologic deficits. The imaging appearance of CNS RDD typically mimics that of meningiomas: well-circumscribed dural-based lesions that often have dural tails. However, some imaging clues also exist that might help a radiologist recognize RDD, even before histopathologic confirmation. This radiology-pathology report of a patient with CNS RDD highlights the most pertinent clinical, imaging, and pathologic features of CNS RDD, and discusses what the neuroradiologist needs to know about the disease.
Shaping the Future of Infectious Diseases: The Journey to Promote Value, Opportunity, and Positive Messaging
Paras, Molly L , Chirch, Lisa M , Aziz, Mariam, Balba, Gayle , Benson, Constance A. , Butt, Saira , James, Scott H. , McCarty, Todd P , Razonable, Raymund R. , Reece, Rebecca , Shnekendorf, Rachel, Viehman, J Alex, acknowledgments), For the Infectious Diseases Society of America Fellowship Training Program Directors Community of Practice and Working Group (complete list of contributing authors in the Working Group listed in, Abdoler, Emily , Acharya, Kartikey, Angarone, Michael , Babik, Jennifer M. , Bartash, Rachel , Bhanot, Nitin , Blackburn, Brian G. , Blyth, Dana M , Bran, Andres, Burke, Victoria, Carey, A., Cheney, Leonard, Chow, Brian , Clough, Lisa , Sanctis, Jorgelina T. de, George, Ige A, Goebel, Melanie , Goshorn, Eli S, Gutiérrez, Ramiro L. , Herc, Erica , Hillenbrand, Molly , Khalil, Sarwat, Lebron, Dora, Lee, Mikyung , Leuck, Anne‐Marie , Gil, Raul Macias , Mapa, Christopher, Matt, Brionna, Maziarz, Eileen K , Melia, Michael T. , Mitra, Subhashis , Monday, Lea , Montague, Brian T. , Murphy, Holly A, Novick, Elizabeth E, Nnedu, Obinna, Ongunti, Sharon, Osorio, Georgina, Pepe, Rosalie, Perez, Federico, Pilkington, Edward F., Raybould, Jillian E. , Reid, Gail , Robinson, Sara , Sanchez, Martha , Schultz, Sara , Sellers, Christopher J., Simon, Matthew , Sisco, Lauren, Slosar-Cheah, Magdalena, Sobhanie, Mohammad Mahdee , Stead, Wendy , Theodore, Deborah , Wald‐Dickler, Noah , Weber, Devin , Witherspoon, Kelsey, Yabes, Joseph , Zuckerman, Richard A. , McCarty, T P , Benson, Constance , Razonable, Raymund R , Swartz, Talia H , Luther, Vera P , Pérez, Federico , Swartz, Talia H. , Luther, Vera , acknowledgments), For the Infectious Diseases Society of America Fellowship Training Program Directors Community of Practice and Working Group (complete list of contributing authors in the Working Group listed in, Blumberg, Emily A. , Bourque, Daniel L. , Burke, Victoria, Carey, Adrienne L, Cunha, Cheston B. , Dobrzynski, David , George, Ige Abraham , Kaltsas, Anna , Khalil, Sarwat, Kiley, John L , Marcos, Luis A. , Murphy, Holly A, Nori, Priya , Robinson, Sara, Sisco, Lauren , Stapleton, Ann E. , Streit, Judy A. , Weisenberg, Scott A.

Mayo Clinic

Open Forum Infectious Diseases | November 13, 2024 | Volume: 11 | Issue: 12 | Pages: No page available

10.1093/ofid/ofae669 | PMID 39610405 Get It

Abstract The field of infectious diseases (ID) offers a rewarding career path and is widely viewed as an essential subspecialty in medicine. However, in recent years, these positive aspects have been overshadowed by concerns surrounding low fellowship match rates, undercompensation, and burnout. The Infectious Diseases Society of America Fellowship Training Program Directors Committee met in 2023, discussed the future of ID as a specialty, and sought to develop strategies to highlight the value and opportunities of ID for future generations, as well as underscore the importance of and provide tools for positive messaging to trainees about the subspecialty. This paper presents ideas generated at this meeting and is meant to serve as a reference for ID training program directors, as well as the wider ID community, in uplifting and shaping the future of the field.
Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study
Montagna, Giacomo , Laws, Alison , Ferrucci, Massimo , Mrdutt, Mary M., Sun, Susie X. , Bademler, Süleyman , Balbaloĝlu, Hakan , Balint‐Lahat, Nora, Banys-Paluchowski, Maggie, Barrio, Andrea V. , Benson, John R. , Beşe, Nuran , Boyle, Marissa K. , Diego, Emilia J. , Eden, Claire , Eller, Ruth S. , Goldschmidt, Maite, Hlavin, Callie , Heidinger, Martin , Jelinska, Justyna, Çakmak, Güldeniz Karadeniz , King, Tari A. , Kuerer, Henry M. , Loesch, Julie M, Milardi, Francesco , Murawa, Dawid , Moo, Tracy‐Ann , Menes, Tehillah S. , Passeri, Daniele , Pastoriza, Jessica , Perhavec, Andraž , Pislar, Nina , Polidorio, Natália , Rami, Avina , Ryu, Jai Min , Schulz, Alexandra , Sevilimedu, Varadan , Uğurlu, Mustafa Ümit , Uras, Cihan, Hemert, Annemiek K. E. van , Wong, Stephanie M. , Yoo, Tae-Kyung , Zhang, Jennifer Q. , Cabıoğlu, Neslihan , Peeters, Marie-Jeanne T. F. D. Vrancken , Morrow, Monica , Weber, William P. , Group, on behalf of the ICARO Study, Andreozzi, Mariacarla, Barbalho, Daniel Meirelles , Boileau, J.-F., Brogi, Edi , Cabero, Flávia Vidal, Cocco, Daniela , Bree, Eelco de , Vernet-Tomás, M. , Deutschmann, Christine , Ditsch, Nina, Fick, Franziska, Fitzal, Florian , Flanagan, Meghan R. , Gentile, Damiano , Grabenstetter, Anne , Heil, Jörg, Holtschmidt, Johannes , Krawczyk, Natalia , Kühn, Thorsten, Kümmel, Sherko, Muslumanoglu, Mahmut , Nekljudova, Valentina , Newman, Lisa A. , Poulakaki, Fiorita , Schwartz, Christopher J. , Siegel, Emily , Simonson, Colin , Tampaki, Ekaterini Christina , Tampakis, Athanasios , Tausch, Christoph, Bruele, Astrid Botty van den , Vorburger, Denise , Weiss, Anna, Wimmer, Kerstin , Woodward, Steven G. , Ziauddin, Firdos M., Boughey, JC , Boyle, Marissa K , Eller, Ruth , Heidinger, Martin , Karadeniz Cakmak, Güldeniz , Kesmodel, Susan B , King, Tari A , Milardi, Francesco , Murawa, Dawid , Menes, Tehillah S , Passeri, Daniele , Pastoriza, Jessica M , Perhavec, Andraz , Polidorio, Natália , Rami, Avina , Ugurlu, M Umit , van Hemert, Annemiek , Yoo, Tae-Kyung Robyn , Zhang, Jennifer Q , Peeters, Marie-Jeanne Vrancken , Morrow, Monica , Weber, Walter P , Wong, Stephanie M , Mrdutt, Mary M , Banys‐Paluchowski, Maggie , Boughey, Judy C. , Uras, Cihan , Karanlık, Hasan , Group, on behalf of the ICARO Study, Ahn, Sung Gwe , Corsi, Fabio , Crown, Angelena , Esposito, Emanuela , Fayanju, Oluwadamilola M. , Gentilini, Oreste D , Gülçelik, Mehmet Ali , Heil, Joerg , Leo, Cornelia , Pilewskie, Melissa , Riedel, Fabian , Rocco, Nicola , Schnabel, Freya Ruth , Singer, Christian F. , Soares, Leonardo Ribeiro , Tasoulis, Marios Konstantinos , Urban, Cicero A. , Vergauwen, Glenn , Wärnberg, Fredrik , Williams, Austin David

Mayo Clinic

Journal of Clinical Oncology | November 7, 2024 | Volume: 43 | Issue: 7 | Pages: 810-820

10.1200/jco.24.01052 | PMID 39509672 Get It

PURPOSE The nodal burden of patients with residual isolated tumor cells (ITCs) in the sentinel lymph nodes (SLNs) after neoadjuvant chemotherapy (NAC) (ypN0i+) is unknown, and axillary management is not standardized. We investigated rates of additional positive lymph nodes (LNs) at axillary lymph node dissection (ALND) and oncologic outcomes in patients with ypN0i+ treated with and without ALND. METHODS The Oncoplastic Breast Consortium-05/ICARO cohort study (ClinicalTrials.gov identifier: NCT06464341 ) retrospectively analyzed data from patients with stage I to III breast cancer with ITCs in SLNs after NAC from 62 centers in 18 countries. The primary end point was the 3-year rate of any axillary recurrence. The rate of any invasive recurrence was the secondary end point. RESULTS In total, 583 patients were included, of whom 182 (31%) had completion ALND and 401 (69%) did not. The median age was 48 years. Most patients (74%) were clinically node-positive at diagnosis and 41% had hormone receptor–positive/human epidermal growth factor receptor 2–negative tumors. The mean number of SLNs with ITCs was 1.2. Patients treated with ALND were more likely to present with cN2/3 disease (17% v 7%, P < .001), have ITCs detected on frozen section (62% v 8%, P < .001), have lymphovascular invasion (38% v 24%, P < .001), and receive adjuvant chest wall (89% v 78%, P = .024) and nodal radiation (82% v 75%, P = .038). Additional positive nodes were found at ALND in 30% of patients, but only 5% had macrometastases. The 3-year rates of any axillary and any invasive recurrence were 2% (95% CI, 0.95 to 3.6) and 11% (95% CI, 8 to 14), respectively, with no statistical difference by type of axillary surgery. CONCLUSION The nodal burden in patients with ypN0(i+) was low, and axillary recurrence after ALND omission was rare in patients selected for this approach. These results do not support routine ALND in all patients with ypN0(i+).
Improved visualization of cochlear implant electrodes on photon counting detector CT
Schroeder, Dane G. , Farnsworth, Paul J. , Benson, John C. , Carlson, Matthew L. , Kassmeyer, Blake , Lane, Jack I., Benson, John , Farnsworth, Paul , Carr, Carrie M. , DeLone, David R. , Leng, Shuai , Mark, Ian T.

Mayo Clinic

Clinical Neuroimaging | October 25, 2024 | Volume: 1 | Issue: 1-2 | Pages: No page available

10.1002/neo2.70005 Get It

AbstractBackgroundCochlear implants (CIs) are used to rehabilitate moderate to profound sensorineural hearing loss and stimulate the auditory system via a multichannel electrode array positioned in the scala tympani. Imaging evaluation of CIs is substantially degraded by metallic artifacts. Photon‐counting detector (PCD)‐CT has the potential to minimize such artifacts, though this has not been convincingly established in prior studies. This study compared the visualization of CI electrodes on PCD‐CT to conventional energy integrating detector (EID)‐CT.Materials and MethodsFive patients with CIs were prospectively recruited to undergo temporal bone imaging on both EID‐CT and PCD‐CT scanners yielding 2D and 3D Volume Rendering Technique (VRT) images. Three nonblinded neuroradiologists reviewed 2D and 3D VRT images for the ability to resolve CI electrode leads using a Likert scale. The average Likert scores of PCD‐CT versus EID‐CT were calculated for each reader for both 2D and 3D VRT images. (Likert scores 1–5 based on inferior to superior rating of PCD‐CT compared to EID‐CT). Inter‐rater agreement was assessed using Krippendorff's alpha with ordinal weights. ResultsFive patients underwent temporal bone CT for CI array evaluation. As evidenced by 5‐point Likert scales that were independently used by the three reviewers, this study demonstrated superior resolution of CI electrode array using PCD‐CT as compared to EID‐CT with an average score of 4.2 ± 0.8 for 2D images and 4.9 ± 0.4 for 3D VRT images.ConclusionsPCD‐CT is superior to EID‐CT in the visualization of CI electrodes, particularly in 3D VRT imaging.